Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, No. 128 Shenyang Road, Shanghai, 200090, China.
Arch Gynecol Obstet. 2023 Jun;307(6):1901-1909. doi: 10.1007/s00404-022-06816-6. Epub 2022 Nov 3.
To evaluate association of preoperative conization with recurrences after laparoscopic radical hysterectomy (LRH) for FIGO 2018 stage IB1 cervical cancer.
This is a retrospective single-center study. Patients who underwent LRH for cervical cancer with squamous, adenosquamous and adenocarcinoma subtype from January 2014 to December 2018 were reviewed. All patients were restaged according to the 2018 FIGO staging system. Those who were in FIGO 2018 stage IB1 met the inclusion criteria. General characteristics and oncologic outcomes including recurrence-free survival (RFS) were analyzed.
A total of 1273 patients were included in the analysis. 616 (48.4%) patients underwent preoperative biopsy, and 657 (51.6%) patients underwent conization. Residual disease was observed in 822 (64.6%) patients. During a median follow-up of 50.30 months, 30 (2.4%) patients experienced recurrence. The univariate analysis showed that patients who had larger tumor diameter, the presence of residual tumor at final pathology, and underwent adjuvant treatment had a significant higher risk of recurrence (P < 0.01). Conversely, patients who underwent conization were significantly less likely to experience recurrence (P = 0.001). In the multivariate analysis, the independent risk factor associated with an increased risk of recurrence was resident macroscopic tumor (HR: 38.4, 95% CI 4.20-351.64, P = 0.001). On the contrary, preoperative conization was associated with a significantly lower risk of recurrence (HR: 0.26; 95% CI 0.10-0.63, P = 0.003). The Kaplan-Meier curves showed patients who underwent conization had improved survival over those who underwent biopsy (5 year RFS: 98.6 vs 95.1%, P = 0.001). The 5 year RFS of patients with residual tumor was significantly different (R0: 99.2%, R1: 97.4%, R2: 93.6%, P < 0.001), especially the patients with residual macroscopic tumor after conization (R0: 99.5%, R1: 99.0%, R2:92.4%, P = 0.006).
Preoperative conization and the absence of residual tumor at the time of surgery might play a protective role in patients with FIGO 2018 IB1 cervical cancer following LRH, which support the theory of the influence of intraoperative tumor spread during radical hysterectomy. Further prospective evidence is needed.
评估术前锥切术与腹腔镜根治性子宫切除术(LRH)后 FIGO 2018 期 IB1 宫颈癌复发的关系。
这是一项回顾性单中心研究。纳入 2014 年 1 月至 2018 年 12 月接受 LRH 治疗的鳞状细胞癌、腺鳞癌和腺癌患者。所有患者均根据 2018 年 FIGO 分期系统重新分期。符合 FIGO 2018 期 IB1 标准的患者纳入本研究。分析一般特征和肿瘤学结局,包括无复发生存率(RFS)。
共纳入 1273 例患者,其中 616 例(48.4%)患者接受术前活检,657 例(51.6%)患者接受锥切术。822 例(64.6%)患者存在残留病灶。中位随访 50.30 个月期间,30 例(2.4%)患者复发。单因素分析显示,肿瘤直径较大、最终病理存在残留肿瘤和接受辅助治疗的患者复发风险显著更高(P<0.01)。相反,接受锥切术的患者复发风险显著较低(P=0.001)。多因素分析显示,与复发风险增加相关的独立危险因素是残留的肉眼肿瘤(HR:38.4,95%CI 4.20-351.64,P=0.001)。相反,术前锥切与复发风险显著降低相关(HR:0.26;95%CI 0.10-0.63,P=0.003)。Kaplan-Meier 曲线显示,接受锥切术的患者生存情况优于接受活检的患者(5 年 RFS:98.6%比 95.1%,P=0.001)。残留肿瘤患者的 5 年 RFS 差异显著(R0:99.2%,R1:97.4%,R2:93.6%,P<0.001),特别是锥切术后存在肉眼残留肿瘤的患者(R0:99.5%,R1:99.0%,R2:92.4%,P=0.006)。
FIGO 2018 期 IB1 宫颈癌患者 LRH 术后,术前锥切术和术中无残留肿瘤可能发挥保护作用,这支持术中肿瘤扩散对根治性子宫切除术的影响理论。需要进一步的前瞻性证据。